The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- Nigeria recorded 589 oil spills in 2024, Study reveals
- Okeowo, Aiyeola, Babaoja lament TikTok ban in US
- NIS alerts public to emergence of ‘ACHAD’ sect in Kaduna
- TikTok shuts down in US as Trump signals possible reinstatement
- Military targets Turji’s hideout, kills son in Zamfara operation
- Death toll from Niger tanker explosion rises to 86
- AfDB calls for action to lower food prices, boost agriculture in Nigeria
- Nigeria’s healthcare reforms driven by record N1.17trn 2024 budget – SWAp